DDIT3 and breast cancer: However, under these conditions, ISRIB does not impair either ERO1 expression or its activity, indicating that ERO1 is not regulated through CHOP in hypoxic breast cancer, and therefore ISRIB only blunts the CHOP signal but not that of ERO1, or the functionally related tumour angiogenesis.